Small cap round-up: Netcall, Orchid, Angel Biotechnology

Netcall, the help-line queue-busting software provider, has upgraded its software suite so that help-desk staff will now be able to manage queries sent via multiple media types (web, e-mail, phone, etc.) through a single, universal queue. The software will allow staff to allocate queries to the appropriate response team.

By MoneyWeek

published 19 March 2012

Orchid Developments Group, a property developer and investor, has alerted to shareholders to a potential cash flow problem for the company. Although the company is able to continue to operate within its current levels of funding in the immediate term, the amount of free cash flow which may be generated in the medium term from the sales of apartments and other assets remains unclear. In addition, the margin of forecast available cash over requirements remains small. The firm has signed a number of new tenants since the start of the year, while the Grand Mall Varna site now has in excess of 81.6% of its total area leased.

Angel Biotechnology is seeking to raise £1m through a placing of shares at 0.2p per share. The new placing follows on from a similar fund raising announced back in December. The company said that some of the companies which participated in the previous placing have asked to buy more shares, while one company which missed out on the first placing is keen to invest £360,000 this time round.